Brought to you by 
Aegerion Pharmaceuticals closes $22.5mm Series A
20 Jun 2006
Executive Summary
Aegerion Pharmaceuticals (therapeutics for cardiovascular and metabolic diseases) raised $22.5mm through an oversubscribed Series A round led by Advent International. Index Ventures, Alta Partners, and MVM Life Science Partners also participated.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aegerion Pharmaceuticals closes $22.5mm Series A
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice